High dose (54 Gy) pre-operative helical tomotherapy for retroperitoneal liposarcoma: Results of a phase II multicenter study
| dc.rights.license | open | en_US |
| dc.contributor.author | SARGOS, Paul | |
| dc.contributor.author | STOECKLE, Eberhard | |
| dc.contributor.author | DUCASSOU, Anne | |
| dc.contributor.author | GIRAUD, Antoine | |
| dc.contributor.author | MERVOYER, Augustin | |
| dc.contributor.author | ITALIANO, Antoine | |
| dc.contributor.author | ALBERT, Sabrina | |
| dc.contributor.author | FERRON, Gwenael | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | KANTOR, Guy | |
| dc.date.accessioned | 2023-10-17T09:58:26Z | |
| dc.date.available | 2023-10-17T09:58:26Z | |
| dc.date.issued | 2023-09-01 | |
| dc.identifier.issn | 1879-0887 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/184460 | |
| dc.description.abstractEn | To evaluate efficacy and feasibility of high-dose intensity-modulated radiotherapy (RT) with pre-operative helical tomotherapy, delivering 54 Gy/30 fractions in patients with retroperitoneal liposarcomas (RPLS). Patients with operable, biopsy-proven, RPLS were included in this phase II multicenter study (ClinicalTrials.gov: NCT01841047). The primary objectives were to analyze loco-regional relapse free survival (LRFS), overall survival (OS) and toxicities, graded according to CTCAE V3.0. From April 2009 to September 2013, 48 patients were included. Histological types were: 20 well differentiated and 28 dedifferentiated liposarcomas. Median clinical target volume (CTV) was 2570 cc (range, 230-8734 cc). The radio-surgical schedule was completed as planned in all patients apart from one. A monobloc wide excision was achieved for all patients. Surgical margins were R0 (16; 34%), R1 (28; 60%), R2 (2; 4%) or missing (1, 2%).With a median follow-up of 5.5 years, 3-year LRFS rate was 74.2% (95%CI: [59.1%; 84.5%]). At 5 years, cumulative incidence of loco-regional relapse for well differentiated and dedifferentiated RPLS was 10% and 18%, respectively. The 5-year OS was 73.9% [95%CI: 58.7-84.3%]. During RT, the most common grade 3-4 adverse events were hematological (N = 20; 41.6%). After surgery and during follow-up, 17 patients (35.4%) presented a grade 3-4 toxicity. Two patients (4.1%) died due to a duodenal toxicity. Nine second cancers were observed. From this phase II trial of preoperative RT in RPLS patients, the dose level proposed cannot be considered safe, leading to non-negligible toxicity and second cancers rates. Our results, combined with STRASS-1 study, suggest that the ideal indication of RT for patients with RPLS still remains to be determined. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Humans | |
| dc.subject.en | Radiotherapy | |
| dc.subject.en | Intensity-Modulated | |
| dc.subject.en | Neoplasms | |
| dc.subject.en | Second Primary | |
| dc.subject.en | Neoplasm Recurrence | |
| dc.subject.en | Local | |
| dc.subject.en | Liposarcoma | |
| dc.title.en | High dose (54 Gy) pre-operative helical tomotherapy for retroperitoneal liposarcoma: Results of a phase II multicenter study | |
| dc.title.alternative | Radiother Oncol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.radonc.2023.109791 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 37437608 | en_US |
| bordeaux.journal | Radiotherapy and Oncology | en_US |
| bordeaux.page | 109791 | en_US |
| bordeaux.volume | 186 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04245853 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-10-17T09:58:28Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Radiotherapy%20and%20Oncology&rft.date=2023-09-01&rft.volume=186&rft.spage=109791&rft.epage=109791&rft.eissn=1879-0887&rft.issn=1879-0887&rft.au=SARGOS,%20Paul&STOECKLE,%20Eberhard&DUCASSOU,%20Anne&GIRAUD,%20Antoine&MERVOYER,%20Augustin&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||